Guest guest Posted February 7, 2010 Report Share Posted February 7, 2010 infoholix.net News Flash 6.2.2010 Over the past week there were some developments regarding the Vaccines/Autism issue. When governments aim to deceive the public with misleading information and persecution of physicians we should be worried.http://www.infoholix.net/article_vaccines_and_autism.php February 4th was international cancer day. The mass media ignored the day as Oncology had nothing positive to report. PSA as a marker for prostate cancer has been exposed as totally unreliable and useless, a fact that is widely known in Europe by now, but ignored by the "Chemo-Radiation-Cancer-Industry" in the USA in spite of scientific studies published there.http://infoholix.net/category.php?mId=117After the Chemo-Radiation treatment has failed men's lives still can be saved with "salvage treatments" for prostate cancer. Ablatherm High Intensity Focused Ultrasound has been licensed as salvage treatment for failed radiotherapy in Europe for some ten years now - and is still not available in the USA.http://infoholix.net/category.php?mId=116Have a relaxing weekend.Cheers,WilfridWilfrid Hartnagelceo, infoholix.netwww.infoholix.net --------------You have received this infoholix.net newsletter as r to infoholix.net, Llanidloes, Powys SY18 6JT, Mid-Wales, UK.To To manage your preferences If this email did not arrive in your inbox then don't forget to set your spam filter to allow mail from infoholix.net.If someone forwarded you this email, and you'd like to receive your own infoholix.net newsletter, please sign up on our website: http://infoholix.net/news_.phpWe have a strict anti-spam policy. We know how important your privacy is to you. That's why we do not share your email address with anyone. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.